SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...
The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new ...
Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov 12th, 2024 --- ...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years ...
Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...
IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF Clinical abstract reviews the ability of Bayesian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results